new retatrutide 🎙️ EPISODE: Retatrutide—The Triple Agonist *Not licensed* Will this replace the current GLP-1 in the market., This triple receptor agonist (GIP/GLP-1/glucagon) is showing unprecedented results in Retatrutide Phase 3: 60% Achieved

This adds cost but also adds a layer of quality verification, faster shipping, easier returns, and domestic legal accountability

BMJ 381 , e074572 (2023)

Here's what you need to know: Medicare Coverage (Effective Mid-2026) Following the November 2025 Trump administration agreements, Medicare will cover GLP-1 medications for obesity with: $50 monthly copay for eligible patients $245 government cost (down from $1,000+ list prices) Medicare Eligibility Requirements: BMI over 27 with prediabetes OR established cardiovascular disease, OR BMI over 30 with uncontrolled hypertension, kidney disease, or heart failure, OR BMI over 35 (severe obesity) Medicaid Coverage States can opt into $245 monthly pricing for all covered uses

This will come as great news for patients who have wanted to try GLP-1 treatments but were needle averse